Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of Clinical Oncology Year : 2016

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome

Bruno Royer
  • Function : Correspondent author
  • PersonId : 1033722

Connectez-vous pour contacter l'auteur
Momar Diouf
  • Function : Author
Margaret Macro
  • Function : Author
Laurent Frenzel
Laurent Garderet
Jean Pierre Marolleau
  • Function : Author
  • PersonId : 887235
  • IdRef : 06981676X

Abstract

PURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance. PATIENTS AND METHODS: Patients 70 years old and younger with newly diagnosed pPCL received four alternating cycles of bortezomib, dexamethasone plus doxorubicin or cyclophosphamide. Peripheral blood stem cells were collected from responding patients with < 1% of circulating plasma cells before HDM/ASCT. As consolidation, young patients received a reduced-intensity conditioning allograft, whereas the remaining patients underwent a second HDM/ASCT followed by 1 year of bortezomib, lenalidomide, dexamethasone. The primary end point was progression-free survival (PFS). RESULTS: Forty patients (median age, 57 years; range, 27 to 71 years) were enrolled. The median follow-up was 28.7 months. In the intention-to-treat analysis, the median PFS and overall survival were 15.1 (95% CI, 8.4; -) and 36.3 (95% CI, 25.6; -) months, respectively. The overall response rate to induction was 69%. One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subsequently received a reduced-intensity conditioning allograft and seven a second ASCT followed by maintenance). CONCLUSION: In this prospective trial in patients with pPCL, we show that bortezomib, dexamethasone plus doxorubicin or cyclophosphamide induction followed by transplantation induces high response rates and appears to significantly improve PFS.

Domains

Cancer
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01822878 , version 1 (25-06-2018)

Identifiers

Cite

Bruno Royer, Stéphane Minvielle, Momar Diouf, Murielle Roussel, Lionel Karlin, et al.. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. Journal of Clinical Oncology, 2016, 34 (18), pp.2125 - 2132. ⟨10.1200/JCO.2015.63.1929⟩. ⟨inserm-01822878⟩
125 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More